Clarity Wealth Advisors LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, Holdings Channel.com reports. The fund acquired 970 shares of the medical research company’s stock, valued at approximately $241,000.
Several other institutional investors have also added to or reduced their stakes in AMGN. Norges Bank purchased a new stake in shares of Amgen during the fourth quarter valued at $1,302,778,000. Morgan Stanley boosted its position in Amgen by 13.8% in the fourth quarter. Morgan Stanley now owns 9,745,556 shares of the medical research company’s stock worth $2,240,698,000 after purchasing an additional 1,179,665 shares during the last quarter. Boston Partners boosted its position in Amgen by 4,644.8% in the fourth quarter. Boston Partners now owns 972,579 shares of the medical research company’s stock worth $223,616,000 after purchasing an additional 952,081 shares during the last quarter. FIL Ltd boosted its position in Amgen by 199.4% in the fourth quarter. FIL Ltd now owns 853,277 shares of the medical research company’s stock worth $196,185,000 after purchasing an additional 568,324 shares during the last quarter. Finally, Beutel Goodman & Co Ltd. boosted its position in Amgen by 67.0% in the fourth quarter. Beutel Goodman & Co Ltd. now owns 1,028,961 shares of the medical research company’s stock worth $236,578,000 after purchasing an additional 412,976 shares during the last quarter. 75.23% of the stock is currently owned by institutional investors.
In other Amgen news, EVP Jonathan P. Graham sold 11,110 shares of the stock in a transaction that occurred on Thursday, February 4th. The stock was sold at an average price of $236.51, for a total transaction of $2,627,626.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction that occurred on Wednesday, April 14th. The shares were sold at an average price of $249.98, for a total value of $249,980.00. Following the transaction, the director now directly owns 16,927 shares of the company’s stock, valued at approximately $4,231,411.46. The disclosure for this sale can be found here. Insiders have sold 14,360 shares of company stock worth $3,407,034 in the last quarter. 0.36% of the stock is currently owned by company insiders.
Shares of AMGN traded down $0.51 during mid-day trading on Tuesday, reaching $244.87. The company had a trading volume of 53,332 shares, compared to its average volume of 2,714,429. Amgen Inc. has a 52-week low of $210.28 and a 52-week high of $276.69. The company has a quick ratio of 1.88, a current ratio of 2.28 and a debt-to-equity ratio of 3.12. The stock has a market capitalization of $141.00 billion, a P/E ratio of 19.89, a PEG ratio of 1.90 and a beta of 0.76. The stock has a 50 day moving average of $248.86 and a two-hundred day moving average of $236.11.
Amgen (NASDAQ:AMGN) last issued its earnings results on Monday, April 26th. The medical research company reported $3.70 EPS for the quarter, missing analysts’ consensus estimates of $4.05 by ($0.35). The company had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $6.30 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%. The firm’s quarterly revenue was down 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.17 EPS. On average, sell-side analysts expect that Amgen Inc. will post 16.15 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Monday, May 17th will be given a dividend of $1.76 per share. The ex-dividend date is Friday, May 14th. This represents a $7.04 dividend on an annualized basis and a yield of 2.87%. Amgen’s dividend payout ratio is currently 47.50%.
Several research analysts have issued reports on the company. Barclays dropped their target price on Amgen from $242.00 to $230.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 11th. Piper Sandler decreased their price objective on Amgen from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 3rd. BMO Capital Markets decreased their price objective on Amgen from $301.00 to $296.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 28th. Credit Suisse Group decreased their price objective on Amgen from $265.00 to $259.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday, April 28th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $255.62.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
Featured Article: How to interpret Moving Average Convergence Divergence (MACD)
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.